213 related articles for article (PubMed ID: 30157880)
1. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.
Cornelius V; Wilson R; Cro S; Barker J; Burden D; Griffiths CEM; Lachmann H; McAteer H; Reynolds N; Pink A; Warren RB; Capon F; Smith C
Trials; 2018 Aug; 19(1):465. PubMed ID: 30157880
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial.
Cro S; Smith C; Wilson R; Cornelius V
Trials; 2018 Oct; 19(1):534. PubMed ID: 30285894
[TBL] [Abstract][Full Text] [Related]
3. A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial.
Cro S; Patel P; Barker J; Burden DA; Griffiths CEM; Lachmann HJ; Reynolds NJ; Warren RB; Capon F; Smith C; Cornelius V
Trials; 2020 Feb; 21(1):158. PubMed ID: 32041649
[TBL] [Abstract][Full Text] [Related]
4. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).
Cro S; Cornelius VR; Pink AE; Wilson R; Pushpa-Rajah A; Patel P; Abdul-Wahab A; August S; Azad J; Becher G; Chapman A; Dunnil G; Ferguson AD; Fogo A; Ghaffar SA; Ingram JR; Kavakleiva S; Ladoyanni E; Leman JA; Macbeth AE; Makrygeoegou A; Parslew R; Ryan AJ; Sharma A; Shipman AR; Sinclair C; Wachsmuth R; Woolf RT; Wright A; McAteer H; Barker JNWN; Burden AD; Griffiths CEM; Reynolds NJ; Warren RB; Lachmann HJ; Capon F; Smith CH;
Br J Dermatol; 2021 Aug; 186(2):245-56. PubMed ID: 34411292
[TBL] [Abstract][Full Text] [Related]
5. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis.
Tauber M; Viguier M; Alimova E; Petit A; Lioté F; Smahi A; Bachelez H
Br J Dermatol; 2014 Sep; 171(3):646-9. PubMed ID: 24684162
[TBL] [Abstract][Full Text] [Related]
6. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
[TBL] [Abstract][Full Text] [Related]
7. Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)-study protocol for a multicenter randomized double-blind placebo-controlled trial.
de Mooij CEM; van Groningen LFJ; de Haan AFJ; Biemond BJ; Bakker M; van der Velden WJFM; Blijlevens NMA
Trials; 2020 Nov; 21(1):948. PubMed ID: 33225965
[TBL] [Abstract][Full Text] [Related]
8. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
Choon SE; Lebwohl MG; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Rajeswari S; Deng H; Tetzlaff K; Thoma C; Bachelez H
BMJ Open; 2021 Mar; 11(3):e043666. PubMed ID: 33785490
[TBL] [Abstract][Full Text] [Related]
9. Randomised, double-blind, multicentre, phase Ⅰ/Ⅱ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol.
Dong W; Nie X; Wang J; Xia L; Cai L; Wang Q; Wang W; Fu W; Wang Q; Shen T; Fan H; Niu S; Cui Y; Zheng Q; Zhang J; Fang Y
BMJ Open; 2020 Nov; 10(11):e039067. PubMed ID: 33234634
[TBL] [Abstract][Full Text] [Related]
10. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
11. Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.
Parker S; Zhang AL; Zhang CS; Goodman G; Wen Z; Lu C; Xue CC
Trials; 2014 Dec; 15():495. PubMed ID: 25526951
[TBL] [Abstract][Full Text] [Related]
12. Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.
Cro S; Smith CH
Br J Dermatol; 2022 May; 186(5):909-910. PubMed ID: 34878650
[TBL] [Abstract][Full Text] [Related]
13. Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.
Roerink ME; Knoop H; Bredie SJ; Heijnen M; Joosten LA; Netea MG; Dinarello CA; van der Meer JW
Trials; 2015 Oct; 16():439. PubMed ID: 26438161
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
15. Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study.
Balasubramaniam G; Parker T; Turner D; Parker M; Scales J; Harnett P; Harrison M; Ahmed K; Bhagat S; Marianayagam T; Pitzalis C; Mallen C; Roddy E; Almond M; Dasgupta B
BMJ Open; 2017 Sep; 7(9):e017121. PubMed ID: 28877949
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
[TBL] [Abstract][Full Text] [Related]
17. Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.
Yatsuzuka K; Murakami M
Br J Dermatol; 2022 May; 186(5):908. PubMed ID: 34878653
[No Abstract] [Full Text] [Related]
18. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.
Bissonnette R; Nigen S; Langley RG; Lynde CW; Tan J; Fuentes-Duculan J; Krueger JG
J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1298-305. PubMed ID: 24112799
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
